{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:49:59Z","timestamp":1791614999520,"version":"4.3.4"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":209,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Berta-Ottenstein-Program of the Medical University Center, Faculty of Medicine, University of Freiburg"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A subset of patients with interstitial lung diseases (ILDs) experiences disease progression despite standard treatment protocols. Similar to idiopathic pulmonary fibrosis, the archetype of progressive fibrotic ILDs, these patients exhibit worsening clinical symptoms, declining lung function, and progressive radiological changes, often resulting in shortened survival. This progressive disease pattern is classified under the term progressive pulmonary fibrosis or progressive fibrosing ILD. Radiological imaging, particularly high-resolution computed tomography (HRCT), is integral to diagnosing ILDs and plays a critical role within multidisciplinary ILD boards. HRCT is instrumental in identifying patients at a higher risk for disease progression and may provide valuable prognostic insights. Additionally, serial imaging is essential for detecting progression over time. While visual assessment remains the primary method for evaluating disease advancement, emerging quantitative techniques, including those utilizing machine learning, are currently undergoing validation.<\/jats:p>","DOI":"10.1093\/bjro\/tzaf018","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:51:03Z","timestamp":1753357863000},"source":"Crossref","is-referenced-by-count":2,"title":["Progressive pulmonary fibrosis: current perspectives in diagnostic imaging"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6784-6727","authenticated-orcid":false,"given":"Prerana","family":"Agarwal","sequence":"first","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg , 79106 Freiburg im Breisgau,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-1481","authenticated-orcid":false,"given":"Christopher L","family":"Schlett","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg , 79106 Freiburg im Breisgau,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7460-3942","authenticated-orcid":false,"given":"Fabian","family":"Bamberg","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg , 79106 Freiburg im Breisgau,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn C","family":"Frye","sequence":"additional","affiliation":[{"name":"Department for Pneumology, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg , 79106 Freiburg im Breisgau,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"2025081213191527000_tzaf018-B1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1164\/rccm.202401-0048PP","article-title":"The role of inflammation and fibrosis in interstitial lung disease treatment decisions","volume":"210","author":"Behr","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025081213191527000_tzaf018-B2","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025081213191527000_tzaf018-B3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s12931-024-03070-z","article-title":"Identification of progressive pulmonary fibrosis: consensus findings from a modified Delphi study","volume":"25","author":"Wells","year":"2024","journal-title":"Respir Res"},{"key":"2025081213191527000_tzaf018-B4","doi-asserted-by":"crossref","first-page":"2103187","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur Respir J"},{"key":"2025081213191527000_tzaf018-B5","first-page":"782","article-title":"Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibroses: S2k Guideline of the German Respiratory Society","volume":"103","author":"Behr","year":"2024","journal-title":"Respiration"},{"key":"2025081213191527000_tzaf018-B6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1164\/rccm.202206-1143LE","article-title":"Progressive pulmonary fibrosis: should the timelines be taken out of the definition?","volume":"206","author":"Cottin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025081213191527000_tzaf018-B7","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"2025081213191527000_tzaf018-B8","doi-asserted-by":"crossref","first-page":"108232","DOI":"10.1016\/j.pharmthera.2022.108232","article-title":"Progressive massive fibrosis: an overview of the recent literature","volume":"240","author":"Weissman","year":"2022","journal-title":"Pharmacol Ther"},{"key":"2025081213191527000_tzaf018-B9","doi-asserted-by":"publisher","first-page":"2002718","DOI":"10.1183\/13993003.02718-2020","article-title":"Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)","volume":"57","author":"Nasser","year":"2021","journal-title":"Eur Respir J"},{"key":"2025081213191527000_tzaf018-B10","doi-asserted-by":"publisher","first-page":"2100221","DOI":"10.1183\/13993003.00221-2021","article-title":"The burden of progressive fibrotic interstitial lung disease across the UK","volume":"58","author":"Simpson","year":"2021","journal-title":"Eur Respir J"},{"key":"2025081213191527000_tzaf018-B11","doi-asserted-by":"crossref","first-page":"799912","DOI":"10.3389\/fmed.2022.799912","article-title":"The burden of progressive-fibrosing interstitial lung diseases","volume":"9","author":"Cottin","year":"2022","journal-title":"Front Med"},{"key":"2025081213191527000_tzaf018-B12","doi-asserted-by":"crossref","first-page":"e2329119","DOI":"10.2214\/AJR.23.29119","article-title":"Imaging of pulmonary fibrosis: an update, from the AJR special series on imaging of fibrosis","volume":"222","author":"Lee","year":"2024","journal-title":"AJR Am J Roentgenol"},{"key":"2025081213191527000_tzaf018-B13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1183\/09031936.00131912","article-title":"Prevalence and prognosis of unclassifiable interstitial lung disease","volume":"42","author":"Ryerson","year":"2013","journal-title":"Eur Respir J"},{"key":"2025081213191527000_tzaf018-B14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcm8010014","article-title":"Effects of Corticosteroid Treatment and Antigen Avoidance in a Large Hypersensitivity Pneumonitis Cohort: A Single-Centre Cohort Study","volume":"8","author":"De Sadeleer","year":"2018","journal-title":"JCM"},{"key":"2025081213191527000_tzaf018-B15","doi-asserted-by":"crossref","first-page":"13051","DOI":"10.1073\/pnas.0804280105","article-title":"Short telomeres are a risk factor for idiopathic pulmonary fibrosis","volume":"105","author":"Alder","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"2025081213191527000_tzaf018-B16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.semarthrit.2010.03.002","article-title":"Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence","volume":"40","author":"Christmann","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"2025081213191527000_tzaf018-B17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025081213191527000_tzaf018-B18","doi-asserted-by":"crossref","first-page":"2101396","DOI":"10.1183\/13993003.01396-2021","article-title":"Lung function trajectory in progressive fibrosing interstitial lung disease","volume":"59","author":"Oldham","year":"2022","journal-title":"Eur Respir J"},{"key":"2025081213191527000_tzaf018-B19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chest.2018.08.1076","article-title":"Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory","volume":"155","author":"Salisbury","year":"2019","journal-title":"Chest"},{"key":"2025081213191527000_tzaf018-B20","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00092309","article-title":"Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease","volume":"35","author":"Kim","year":"2010","journal-title":"Eur Respir J"},{"key":"2025081213191527000_tzaf018-B21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S2213-2600(17)30216-3","article-title":"The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study","volume":"5","author":"Ley","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025081213191527000_tzaf018-B22","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1513\/AnnalsATS.201807-443OC","article-title":"Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases","volume":"16","author":"Adegunsoye","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2025081213191527000_tzaf018-B23","doi-asserted-by":"crossref","first-page":"1043720","DOI":"10.3389\/fmed.2022.1043720","article-title":"Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases\u2014development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score","volume":"9","author":"Shao","year":"2022","journal-title":"Front Med"},{"key":"2025081213191527000_tzaf018-B24","doi-asserted-by":"crossref","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing interstitial lung diseases: knowns and unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2025081213191527000_tzaf018-B25","doi-asserted-by":"publisher","first-page":"220003","DOI":"10.1183\/16000617.0003-2022","article-title":"Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives","volume":"31","author":"Cottin","year":"2022","journal-title":"Eur Respir Rev"},{"key":"2025081213191527000_tzaf018-B26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10067-020-05375-y","article-title":"Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests","volume":"40","author":"Carnevale","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025081213191527000_tzaf018-B27","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of hypersensitivity pneumonitis in adults. An official ATS\/JRS\/ALAT Clinical Practice Guideline","volume":"202","author":"Raghu","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025081213191527000_tzaf018-B28","doi-asserted-by":"crossref","first-page":"679051","DOI":"10.3389\/fmed.2021.679051","article-title":"The role of radiology in progressive fibrosing interstitial lung disease","volume":"8","author":"Abu Qubo","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025081213191527000_tzaf018-B29","first-page":"00145","article-title":"Exploring computer-based imaging analysis in interstitial lung disease: opportunities and challenges","volume":"9","author":"Federico","year":"2023","journal-title":"ERJ Open Res"},{"key":"2025081213191527000_tzaf018-B30","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/bjr\/tqae170","article-title":"Assessment of interstitial lung disease in a systemic sclerosis patient cohort using photon-counting detector CT with ultra-high resolution and a 1024-pixel image matrix","volume":"97","author":"Jungblut","year":"2024","journal-title":"Br J Radiol"},{"key":"2025081213191527000_tzaf018-B31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/thoraxjnl-2015-207252","article-title":"Interobserver agreement for the ATS\/ERS\/JRS\/ALAT criteria for a UIP pattern on CT","volume":"71","author":"Walsh","year":"2016","journal-title":"Thorax"},{"key":"2025081213191527000_tzaf018-B32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12890-024-03254-9","article-title":"Quantitative CT analysis of idiopathic pulmonary fibrosis and correlation with lung function study","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2025081213191527000_tzaf018-B33","doi-asserted-by":"crossref","first-page":"1801384","DOI":"10.1183\/13993003.01384-2018","article-title":"Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis","volume":"52","author":"Humphries","year":"2018","journal-title":"Eur Respir J"},{"key":"2025081213191527000_tzaf018-B34","doi-asserted-by":"crossref","first-page":"230055","DOI":"10.1183\/16000617.0055-2023","article-title":"Towards the adoption of quantitative computed tomography in the management of interstitial lung disease","volume":"33","author":"Walsh","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2025081213191527000_tzaf018-B35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1148\/radiol.2463062200","article-title":"Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality","volume":"246","author":"Best","year":"2008","journal-title":"Radiology"},{"key":"2025081213191527000_tzaf018-B36","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1183\/09031936.00071812","article-title":"Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis","volume":"43","author":"Maldonado","year":"2014","journal-title":"Eur Respir J"},{"key":"2025081213191527000_tzaf018-B37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12890-017-0418-2","article-title":"Chronic hypersensitivity pneumonitis: identification of key prognostic determinants using automated CT analysis","volume":"17","author":"Jacob","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2025081213191527000_tzaf018-B38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12916-016-0739-7","article-title":"Evaluation of computer-based computer tomography stratification against outcome models in connective tissue disease-related interstitial lung disease: a patient outcome study","volume":"14","author":"Jacob","year":"2016","journal-title":"BMC Med"},{"key":"2025081213191527000_tzaf018-B39","doi-asserted-by":"crossref","first-page":"1601011","DOI":"10.1183\/13993003.01011-2016","article-title":"Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures","volume":"49","author":"Jacob","year":"2017","journal-title":"Eur Respir J"},{"key":"2025081213191527000_tzaf018-B40","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00330-017-5053-z","article-title":"Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores","volume":"28","author":"Jacob","year":"2018","journal-title":"Eur Radiol"},{"key":"2025081213191527000_tzaf018-B41","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2214\/AJR.16.16054","article-title":"Texture-based automated quantitative assessment of regional patterns on initial CT in patients with idiopathic pulmonary fibrosis: relationship to decline in forced vital capacity","volume":"207","author":"Park","year":"2016","journal-title":"Am J Roentgenol"},{"key":"2025081213191527000_tzaf018-B42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.acra.2014.08.004","article-title":"Comparison of the quantitative CT imaging biomarkers of idiopathic pulmonary fibrosis at baseline and early change with an interval of 7 months","volume":"22","author":"Kim","year":"2015","journal-title":"Acad Radiol"},{"key":"2025081213191527000_tzaf018-B43","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00330-011-2223-2","article-title":"Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide","volume":"21","author":"Kim","year":"2011","journal-title":"Eur Radiol"},{"key":"2025081213191527000_tzaf018-B44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/rccm.202311-2185OC","article-title":"Deep learning-based segmentation of computed tomography scans predicts disease progression and mortality in idiopathic pulmonary fibrosis","volume":"210","author":"Thillai","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025081213191527000_tzaf018-B45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1164\/rccm.202112-2684OC","article-title":"Deep learning\u2013based outcome prediction in progressive fibrotic lung disease using high-resolution computed tomography","volume":"206","author":"Walsh","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025081213191527000_tzaf018-B46","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1164\/rccm.202312-2213SO","article-title":"Report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the national institutes of health, a patient advocacy organization, and a regulatory agency","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025081213191527000_tzaf018-B47","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0194-2024","article-title":"A systematic review of the role of quantitative CT in the prognostication and disease monitoring of interstitial lung disease","volume":"34","author":"Dixon","year":"2025","journal-title":"Eur Respir Rev"},{"key":"2025081213191527000_tzaf018-B48","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"New Engl J Med"},{"key":"2025081213191527000_tzaf018-B49","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2025081213191527000_tzaf018-B50","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025081213191527000_tzaf018-B51","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"New Engl J Med"},{"key":"2025081213191527000_tzaf018-B52","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025081213191527000_tzaf018-B53","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["BJR|Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjro\/advance-article-pdf\/doi\/10.1093\/bjro\/tzaf018\/63839156\/tzaf018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjro\/article-pdf\/7\/1\/tzaf018\/63839156\/tzaf018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjro\/article-pdf\/7\/1\/tzaf018\/63839156\/tzaf018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:19:28Z","timestamp":1755019168000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjro\/article\/doi\/10.1093\/bjro\/tzaf018\/8211674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/bjro\/tzaf018","relation":{},"ISSN":["2513-9878"],"issn-type":[{"value":"2513-9878","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,27]]},"article-number":"tzaf018"}}